The recommendation comes after a review of a clinical trial which found that delivering a smaller dose intradermally – just below the top layer of the skin – is as effective as giving the standard dose subcutaneously as recommended on the monkeypox vaccine’s label.
In the study, the standard 0.5 ml dose given subcutaneously was compared to a 0.1 ml intradermal dose, each with two doses given four weeks apart.
